Global Pulmonary Embolism Drugs Market Trends, Forecast Report 2025-2037
Pulmonary Embolism Drugs Market size is projected to grow from USD 1.76 billion to USD 3.85 billion, reflecting a CAGR of over 6.1% during the forecast period, between 2025 and 2037. In the year 2025, the industry size of pulmonary embolism drugs is estimated at USD 1.84 billion.
The market growth is driven by increasing prevalence of cardiovascular diseases owing to the malfunction of arteries. Cardiovascular diseases are associated with blood vessels or the heart. It is a medical condition in which the circulation of blood to the brain, heart, and body is reduced owing to blood clots. Based on the data provided by the World Health Organization (WHO), in 2019, around 17.9 million people were observed to be suffering from cardiovascular disease.
In addition, rising awareness of healthy lifestyles promoting the importance of early diagnosis and a surge in the cases of cancer are estimated to expand the market size. Pulmonary embolism is observed to cause a significant number of cancers in the global population. For instance, around 5% of cancer-related deaths are accounted by pulmonary emboli which is a type of blood clot in the lungs. Furthermore, people suffering from cancer associated with the brain, lungs, stomach, and people who are noticed to be undergoing chemotherapy are at higher risk of getting pulmonary embolism. For instance, it was projected that there is estimated to be around 22 million cancer survivors owing to chemotherapy by the year 2032.
Pulmonary Embolism Drugs Sector: Growth Drivers and Challenges
Growth Drivers
-
Growing Prevalence of Bone Fractures - Bone fracture is one of the major reasons to cause of pulmonary embolism since during bone injury, fat around the muscle turns into broken blood vessels. When these symptoms are developed owing to a lack of medical attention, they turn into embolism syndrome. For instance, it was anticipated that nearly 1 million individuals suffer from bone fractures annually.
-
Rising Awareness of Pulmonary Embolism Across the Globe - In modern times, owing to the developing medical technology and the launch of new innovative diagnostic devices has spurred awareness of the early diagnosis of pulmonary embolism which is anticipated to hike the market growth over the forecast period. It was estimated that around 35% of people lose their lives before getting any sort of diagnosis and treatment.
-
Increasing Prevalence of Pulmonary Embolism (PE) - The prevalence of pulmonary embolism is so high that it is third behind heart attack and stroke. For instance, approximately 300,000 people lose their lives every year in the United States.
-
Growing Incidences of Heart Failure to Boost Market Growth - Heart failure is also considered to be one of the major causes of pulmonary embolism. For instance, it was estimated that approximately 6 million Americans aged above 20 have heart failure while 900,000 new cases of heart failure are diagnosed every year in the American region.
Challenges
- Side Effects of Pulmonary Embolism Drugs - The possibility of side effects can be quite higher owing to the consumption of pulmonary embolism drugs such as chest pain, shortness of breath, anxiety, dizziness, fainting, and others. Hence, such a higher number of side effects owing to the consumption of these drugs was projected to hamper the growth of the market over the forecast period.
- Higher Possibility of Blood Clotting
- Lack of Awareness regarding Pulmonary Embolism Drugs
Pulmonary Embolism Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.1% |
|
Base Year Market Size (2024) |
USD 1.76 billion |
|
Forecast Year Market Size (2037) |
USD 3.85 billion |
|
Regional Scope |
|
Pulmonary Embolism Drugs Segmentation
Drug Class (Thrombolytics, Thrombosis, Heparins, Thrombin Inhibitors)
The thrombosis segment is estimated to gain largest market share by 2037. Thrombosis is a medical condition that is mainly caused by a lump of thick blood clots that forms in a blood vessel in the heart. Venous thrombosis is observed to be quite prevalent across the globe which is estimated to hike the market revenue. For instance, it was expected that every year, in every 1000, 1 of them suffer from venous thrombosis. The occurrence rate of thrombosis rises after the age of 45 and is quite higher in men than women. The risk factors of thrombosis include immobility, hospitalization, trauma, pregnancy, and others.
Distribution Channel (Hospital Pharmacy, Drug Store, Online Pharmacy)
The hospital pharmacies segment is predicted to account for significant market share by 2037. Hospitals are noticed to have luxury medical services in a single place. A huge staff of medical professionals is available to provide healthcare services 24/7. Furthermore, every nation is observed to spend a significant amount of money to develop hospital infrastructures to provide better medical services. The growth in the number of hospitals across the globe is anticipated to be backed by increasing income, population demographics, growing health awareness, and others.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPulmonary Embolism Drugs Industry - Regional Synopsis
North American Market Forecast
The North American pulmonary embolism drugs market is anticipated to account for majority share by the end of 2037. The market growth is propelled by rising healthcare expenditure backed by escalating government spending to develop healthcare services. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America is valued at USD 10,050.279. Moreover, the presence of major pharmaceutical companies in the region will boost the market growth.
APAC Market Statistics
The Asia Pacific pulmonary embolism drugs market is predicted to observe massive growth during the forecast period, impelled by high prevalence of cancer in the region backed by growing government initiatives to launch and support programs to provide medical services for people living with cancer. For instance, in 2020, approximately 150 thousand people were estimated to be living with cancer in the Asia Pacific along with the high geriatric population, both of which are major causes of pulmonary embolism.
Europe Market Forecast
The Europe pulmonary embolism drugs market is set to hold a notable share by 2037. Factors such as, a higher prevalence of cancer in the region and higher demand for healthcare solution backed by increasing geriatric population will propel the market revenue. Moreover, the surge in research & development of pulmonary embolism drugs in the region will drive the market growth.
Companies Dominating the Pulmonary Embolism Drugs Landscape
- Janssen Global Services, LLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Abbott Laboratories
- Merck & Co., Inc.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Siemens Healthcare GmbH
- Baxter International Inc.
In the News
-
Janssen Pharmaceuticals, Inc. revealed the results from Phase 3 A DUE study. This Phase 3 study is to represent investigational single-tablet combination therapy.
-
Novartis AG got approval for Tafinlar (dabrafenib) + Mekinist (trametinib) from U.S. Food and Drug Administration (FDA). These medications are used to treat pediatric patients or people with brain cancer.
Author Credits: Radhika Pawar
- Report ID: 3400
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT
